Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 3/20 | 0.53 |
| ▸ | ELANE | P08246 | 3/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638795 | 0.93 | ELANE (0.61) | CTRB1ELANELCKP2RX7 | |
| SCHEMBL6634354 | 0.91 | CTRB1 (0.53) | CTRB1ELANEP2RX7 | |
| SCHEMBL7449565 | 0.88 | ELANE (0.58) | CTRB1ELANELCKP2RX7 | |
| SCHEMBL6640343 | 0.87 | CTRB1 (0.55) | CTRB1ELANE | |
| SCHEMBL6637178 | 0.86 | CTRB1 (0.51) | CTRB1ELANECYP17A1LCK | |
| SCHEMBL6636428 | 0.86 | ELANE (0.57) | CTRB1ELANECYP17A1LCKCCNC | |
| SCHEMBL6637693 | 0.85 | CTRB1 (0.49) | CTRB1ELANECYP17A1LCK | |
| SCHEMBL6638394 | 0.84 | CTRB1 (0.56) | CTRB1ELANECYP17A1LCK | |
| SCHEMBL6638831 | 0.84 | CTRB1 (0.54) | CTRB1ELANEP2RX7 | |
| SCHEMBL6640355 | 0.84 | ELANE (0.53) | CTRB1ELANECYP17A1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116420-A1 | Remedial agent for viral infectious disease | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1403269-A1 | REMEDIAL AGENT FOR VIRAL INFECTIOUS DISEASE | Asahi Kasei Pharma Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |